Access Industries Affiliate Discloses Stake in Upstream Bio
Ticker: UPB · Form: SC 13D · Filed: Oct 22, 2024 · CIK: 2022626
| Field | Detail |
|---|---|
| Company | Upstream Bio, Inc. (UPB) |
| Form Type | SC 13D |
| Filed Date | Oct 22, 2024 |
| Risk Level | medium |
| Pages | 11 |
| Reading Time | 13 min |
| Key Dollar Amounts | $0.001, $10.00, $17.00, $5 m, $1 m |
| Sentiment | neutral |
Sentiment: neutral
Topics: ownership-filing, biotechnology, pharmaceuticals
TL;DR
Access Industries affiliate AI Upstream LLC just disclosed a stake in Upstream Bio, Inc. (NASDAQ: UPST - hypothetical ticker).
AI Summary
On October 22, 2024, AI Upstream LLC, an entity associated with Len Blavatnik and Access Industries, filed a Schedule 13D regarding their beneficial ownership of Upstream Bio, Inc. The filing indicates a significant stake in the pharmaceutical preparations company, which is incorporated in Delaware and headquartered in Waltham, MA.
Why It Matters
This filing signals a significant investment or control shift by a major entity in a biotechnology company, potentially impacting its strategic direction and future operations.
Risk Assessment
Risk Level: medium — Schedule 13D filings can indicate activist investor intent or significant changes in control, warranting close monitoring.
Key Players & Entities
- AI Upstream LLC (company) — Filing entity
- Upstream Bio, Inc. (company) — Subject company
- Access Industries Management, LLC (company) — Group member
- Len Blavatnik (person) — Associated individual
- Alejandro Moreno (person) — Contact person
- Langhorne S. Perrow (person) — Contact person
- Nicholas (person) — Contact person
FAQ
What is the exact percentage of Upstream Bio, Inc. shares beneficially owned by AI Upstream LLC?
The provided text does not specify the exact percentage of shares beneficially owned by AI Upstream LLC.
When was the last reported change in beneficial ownership for AI Upstream LLC in Upstream Bio, Inc.?
The date of the last change in beneficial ownership reported in this filing is October 22, 2024.
What is the business address of Upstream Bio, Inc.?
The business address of Upstream Bio, Inc. is 890 Winter Street, Suite 200, Waltham, MA 02451.
Who are the primary contacts listed for the filing on behalf of AI Upstream LLC?
The primary contacts listed are Alejandro Moreno and Langhorne S. Perrow, with copies to Nicholas, c/o Access Industries, Inc.
What is the Standard Industrial Classification (SIC) code for Upstream Bio, Inc.?
The SIC code for Upstream Bio, Inc. is 2834, which corresponds to Pharmaceutical Preparations.
Filing Stats: 3,279 words · 13 min read · ~11 pages · Grade level 14.3 · Accepted 2024-10-22 16:06:27
Key Financial Figures
- $0.001 — me of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securiti
- $10.00 — eferred stock), at a per share price of $10.00 in cash. In two closings in June 2023 a
- $17.00 — eferred stock), at a per share price of $17.00 in cash. AI Upstream funded these purch
- $5 m — of selling expenses, that would exceed $5 million, subject to customary terms and c
- $1 m — e, net of selling expenses, of at least $1 million, subject to customary terms and c
Filing Documents
- d862554dsc13d.htm (SC 13D) — 111KB
- d862554dex991.htm (EX-99.1) — 37KB
- d862554dex993.htm (EX-99.3) — 9KB
- d862554dex994.htm (EX-99.4) — 8KB
- g862554dsp26a.jpg (GRAPHIC) — 3KB
- g862554dsp26b.jpg (GRAPHIC) — 4KB
- 0001193125-24-241045.txt ( ) — 176KB
of this Schedule 13D is incorporated herein by reference
Item 3 of this Schedule 13D is incorporated herein by reference. (d) Not applicable. (e) Not applicable. Item6 Contracts, Arrangements, Understandings or Relationships With Respect to Securities of the Issuer Lock-up Agreement In connection with the Issuers initial public offering, on June 10, 2024, AI Upstream entered into a lock-up agreement (the Lock-up Agreement) with J.P. Morgan Securities LLC, TD Securities (USA) LLC, Piper Sandler & Co., and William Blair & Company, L.L.C. Pursuant to the Lock-up Agreement, AI Upstream has agreed that it will not offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant purchase, lend, or otherwise transfer or dispose of, directly or indirectly, any shares of Common Stock or any securities convertible into or exchangeable or exercisable for shares of Common Stock, request or demand that the Issuer file a registration statement related to the Common Stock or enter into any hedging, swap or other agreement or any transaction that transfers, in whole or in part, the economic consequence of ownership of the Common Stock for a period of 180 days following October 9, 2024, the date of the Issuers prospectus filed pursuant to Rule 424(b)(4) with the SEC, without the prior written consent of J.P. Morgan Securities LLC, TD Securities (USA) LLC, Piper Sandler & Co., and William Blair & Company, L.L.C., on behalf of the underwriters, subject to certain exceptions. J.P. Morgan Securities LLC, TD Securities (USA) LLC, Piper Sandler & Co., and William Blair & Company, L.L.C., on behalf of the underwriters, may release all or any portion of the securities subject to the Lock-up Agreement at any time and without notice before the termination of the 180-day period. The foregoing description of the Lock-up Agreement does not purport to be complete and is qualified in its entirety by reference to such, which is filed as an exhibit and